[go: up one dir, main page]

HRP20181558T1 - Fuzijski proteini za liječenje metaboličkih poremećaja - Google Patents

Fuzijski proteini za liječenje metaboličkih poremećaja

Info

Publication number
HRP20181558T1
HRP20181558T1 HRP20181558TT HRP20181558T HRP20181558T1 HR P20181558 T1 HRP20181558 T1 HR P20181558T1 HR P20181558T T HRP20181558T T HR P20181558TT HR P20181558 T HRP20181558 T HR P20181558T HR P20181558 T1 HRP20181558 T1 HR P20181558T1
Authority
HR
Croatia
Prior art keywords
treatment
fusion proteins
metabolic disorders
metabolic
disorders
Prior art date
Application number
HRP20181558TT
Other languages
English (en)
Inventor
Brian R. Boettcher
Shari L. Caplan
Douglas S. Daniels
Norio Hamamatsu
Stuart Licht
Stephen Craig Weldon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20181558T1 publication Critical patent/HRP20181558T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HRP20181558TT 2011-09-26 2012-09-26 Fuzijski proteini za liječenje metaboličkih poremećaja HRP20181558T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
PCT/US2012/057384 WO2013049247A1 (en) 2011-09-26 2012-09-26 Fusion proteins for treating metabolic disorders
EP12768999.0A EP2760475B1 (en) 2011-09-26 2012-09-26 Fusion proteins for treating metabolic disorders

Publications (1)

Publication Number Publication Date
HRP20181558T1 true HRP20181558T1 (hr) 2018-11-30

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20211575TT HRP20211575T1 (hr) 2011-09-26 2012-09-26 Fuzijski proteini za liječenje metaboličkih poremećaja
HRP20181558TT HRP20181558T1 (hr) 2011-09-26 2012-09-26 Fuzijski proteini za liječenje metaboličkih poremećaja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20211575TT HRP20211575T1 (hr) 2011-09-26 2012-09-26 Fuzijski proteini za liječenje metaboličkih poremećaja

Country Status (42)

Country Link
US (6) US9006400B2 (hr)
EP (2) EP2760475B1 (hr)
JP (4) JP6186361B2 (hr)
KR (1) KR102085605B1 (hr)
CN (2) CN103945871B (hr)
AP (1) AP2014007543A0 (hr)
AR (2) AR088044A1 (hr)
AU (1) AU2012316052A1 (hr)
BR (1) BR112014007069B1 (hr)
CA (1) CA2849464C (hr)
CL (2) CL2014000736A1 (hr)
CO (1) CO6920257A2 (hr)
CR (1) CR20140140A (hr)
CU (2) CU24314B1 (hr)
CY (2) CY1120928T1 (hr)
DK (2) DK3321276T3 (hr)
EA (1) EA039633B1 (hr)
ES (2) ES2689762T3 (hr)
GT (1) GT201400055A (hr)
HK (1) HK1251238A1 (hr)
HR (2) HRP20211575T1 (hr)
HU (2) HUE055584T2 (hr)
IL (1) IL231533B (hr)
IN (1) IN2014DN02043A (hr)
JO (1) JO3476B1 (hr)
LT (2) LT3321276T (hr)
MA (1) MA35437B1 (hr)
MX (1) MX350273B (hr)
MY (1) MY166059A (hr)
PE (2) PE20181159A1 (hr)
PL (2) PL2760475T3 (hr)
PT (2) PT2760475T (hr)
RS (2) RS57868B1 (hr)
SG (2) SG11201400538QA (hr)
SI (2) SI3321276T1 (hr)
SM (1) SMT202100595T1 (hr)
TN (1) TN2014000109A1 (hr)
TW (1) TWI593708B (hr)
UA (1) UA113856C2 (hr)
UY (2) UY34346A (hr)
WO (1) WO2013049247A1 (hr)
ZA (1) ZA201401700B (hr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012540A1 (en) 2006-07-25 2008-01-31 Lipoxen Technologies Limited N-terminal polysialylation
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
MX349869B (es) 2011-07-01 2017-08-17 Ngm Biopharmaceuticals Inc Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas.
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TWI593708B (zh) * 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2868393A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
EP3125921B1 (en) * 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2964782A1 (en) * 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
JP7632835B2 (ja) * 2016-05-20 2025-02-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 加齢関連疾患及び症状の遺伝子治療法
MX2018014475A (es) * 2016-05-25 2019-05-23 Univ Texas Métodos y composiciones para el tratamiento de trastornos secretorios.
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018115401A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
AU2018261021B2 (en) * 2017-05-05 2024-09-12 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
US11752173B2 (en) 2017-12-19 2023-09-12 Beijing Jiyuan Biological Technology Co., Ltd. FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
CA3086649A1 (en) 2017-12-22 2019-06-27 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
WO2019154189A1 (en) 2018-02-08 2019-08-15 Sunshine Lake Pharma Co., Ltd. Fgf21 variant, fusion protein and application thereof
WO2020010117A2 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf21 formulations
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
AU2020408067B2 (en) 2019-12-20 2024-03-28 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CA3184546A1 (en) * 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
CA2392103A1 (en) 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
EP2295079A3 (en) 1999-12-23 2011-03-23 ZymoGenetics, L.L.C. Method for treating inflammation
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
DE602005016917D1 (de) * 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
ES2332057T3 (es) * 2004-09-02 2010-01-25 Eli Lilly And Company Muteinas del factor de crecimiento de fibroblastos 21.
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
KR20130086386A (ko) 2008-10-24 2013-08-01 아이알엠 엘엘씨 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
AU2010246108B2 (en) 2009-05-05 2014-10-23 Amgen Inc. FGF21 mutants and uses thereof
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
TW201130511A (en) 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy

Also Published As

Publication number Publication date
CA2849464A1 (en) 2013-04-04
CU24206B1 (es) 2016-10-28
US20180369332A1 (en) 2018-12-27
KR20140069250A (ko) 2014-06-09
ES2895080T3 (es) 2022-02-17
GT201400055A (es) 2017-09-28
LT3321276T (lt) 2021-11-10
SG10201602339XA (en) 2016-05-30
US9266935B2 (en) 2016-02-23
HK1251238A1 (en) 2019-01-25
US20150166622A1 (en) 2015-06-18
PT2760475T (pt) 2018-10-25
US11129874B2 (en) 2021-09-28
MY166059A (en) 2018-05-22
IL231533A0 (en) 2014-04-30
BR112014007069A2 (pt) 2017-03-28
KR102085605B1 (ko) 2020-03-06
JO3476B1 (ar) 2020-07-05
JP2018023370A (ja) 2018-02-15
EA201490695A1 (ru) 2015-10-30
DK2760475T3 (en) 2018-10-15
CU20150171A7 (es) 2016-07-29
US9006400B2 (en) 2015-04-14
JP6186361B2 (ja) 2017-08-23
UA113856C2 (xx) 2017-03-27
JP2022058546A (ja) 2022-04-12
CU24314B1 (es) 2018-02-08
DK3321276T3 (da) 2021-10-25
CN103945871A (zh) 2014-07-23
MA35437B1 (fr) 2014-09-01
TW201326213A (zh) 2013-07-01
US20130079500A1 (en) 2013-03-28
CY1120928T1 (el) 2019-12-11
IN2014DN02043A (hr) 2015-05-15
US20210386824A1 (en) 2021-12-16
RS62341B1 (sr) 2021-10-29
UY34346A (es) 2013-04-30
NZ622998A (en) 2016-07-29
US10076554B2 (en) 2018-09-18
WO2013049247A1 (en) 2013-04-04
EP2760475B1 (en) 2018-07-04
BR112014007069B1 (pt) 2020-12-15
CR20140140A (es) 2014-07-15
CU20140034A7 (es) 2014-08-28
ES2689762T3 (es) 2018-11-15
MX2014003677A (es) 2014-04-30
HUE055584T2 (hu) 2021-12-28
ZA201401700B (en) 2015-01-28
EP2760475A1 (en) 2014-08-06
AR123908A2 (es) 2023-01-25
SI2760475T1 (sl) 2018-10-30
JP6567613B2 (ja) 2019-08-28
PT3321276T (pt) 2021-10-27
EP3321276A3 (en) 2018-06-20
CO6920257A2 (es) 2014-04-10
HRP20211575T1 (hr) 2022-02-04
SI3321276T1 (sl) 2021-11-30
SMT202100595T1 (it) 2022-01-10
MX350273B (es) 2017-08-31
LT2760475T (lt) 2018-10-25
EP3321276A2 (en) 2018-05-16
PE20141551A1 (es) 2014-10-26
AU2012316052A1 (en) 2014-04-17
AR088044A1 (es) 2014-05-07
SG11201400538QA (en) 2014-06-27
TN2014000109A1 (en) 2015-07-01
CN107266579A (zh) 2017-10-20
IL231533B (en) 2018-06-28
EP3321276B1 (en) 2021-07-28
HUE039857T2 (hu) 2019-02-28
JP2020007314A (ja) 2020-01-16
CL2014000736A1 (es) 2014-10-03
US11944664B2 (en) 2024-04-02
CY1124697T1 (el) 2022-07-22
JP7339372B2 (ja) 2023-09-05
EA039633B1 (ru) 2022-02-18
TWI593708B (zh) 2017-08-01
CL2016002215A1 (es) 2016-10-28
CN103945871B (zh) 2017-04-26
CA2849464C (en) 2024-01-30
US20240261372A1 (en) 2024-08-08
PL3321276T3 (pl) 2022-01-17
JP2014534172A (ja) 2014-12-18
PE20181159A1 (es) 2018-07-19
PL2760475T3 (pl) 2018-11-30
RS57868B1 (sr) 2018-12-31
AP2014007543A0 (en) 2014-03-31
UY39119A (es) 2021-04-30
CN107266579B (zh) 2022-07-12
US20160193297A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
HRP20181558T1 (hr) Fuzijski proteini za liječenje metaboličkih poremećaja
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
HRP20180237T1 (hr) Metode za liječenje hcv-a
DK2771364T3 (da) Fremstilling af heterodimere proteiner
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HRP20181818T1 (hr) Postupak za proizvodnju supstituiranih 5-fluoro-1h-pirazolopiridina
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
BR112014007029A2 (pt) métodos aperfeiçoados de terapia gênica
RS57209B1 (sr) Antagonisti il17c za lečenje zapaljenskih poremećaja
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
DK2783256T3 (da) Terapeutiske briller
BR112013031686A2 (pt) fusão de moléculas bioativas
CO6880064A2 (es) Métodos terapéuticos
EP2739764A4 (en) ION SOURCE
HRP20170248T1 (hr) Aklidinij za primjenu u poboljšanju kvalitete sna kod respiratornih bolesnika
DK3447070T3 (da) Forbindelser til behandling af remyeliniseringsblokaden i sygdomme relateret til udtrykket af herv-w kappeprotein
HRP20171272T1 (hr) Sustavi i metode za povećanje prinosa proteina iz postupka rekombinatne proizvodnje
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
PL2780003T3 (pl) Leczenie niedoczynności kory nadnerczy
FI20115704L (fi) Vierasproteiinien tuoton parantaminen
TH148777B (th) ฟิวชั่นโปรตีนสำหรับบำบัดความผิดปกติเกี่ยวกับเมทาบอลิซึม